Skip to main content
SpringerLink
Log in

Mirabegron: a guide to its use in overactive bladder syndrome in the EU

  • Adis Drug Clinical Q&A
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Mirabegron (Betmiga™), a β3-adrenergic receptor agonist, is a useful option for the treatment of overactive bladder syndrome. In clinical trials in this patient population, oral mirabegron 50 mg once daily significantly reduced incontinence and micturition episodes, consistently reduced urgency episodes and increased the volume of urine voided per micturition, and was associated with improvements in health-related quality of life and treatment satisfaction. Mirabegron is generally well tolerated and is associated with less dry mouth than extended-release tolterodine.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010;29(1):4–20.

    PubMed  Google Scholar 

  2. Wagg A, Majumdar A, Toozs-Hobson P, et al. Current and future trends in the management of overactive bladder. Int Urogynecol J. 2007;18(1):81–94.

    Article  Google Scholar 

  3. Wein AJ, Chapple C. Overactive bladder in clinical practice. London: Springer; 2012.

    Book  Google Scholar 

  4. Marinkovic SP, Rovner ES, Moldwin RM, et al. The management of overactive bladder syndrome. BMJ. 2012;344(7853):38–44.

    CAS  Google Scholar 

  5. Hashim H, Abrams P. Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations. Drugs. 2004;64(15):1643–56.

    Article  CAS  PubMed  Google Scholar 

  6. Betmiga (mirabegron) 25 mg and 50 mg prolonged-release tablets: summary of product characteristics. London: European Medicines Agency; 2014.

  7. Nitti VW, Rosenberg S, Mitcheson DH, et al. Urodynamics and safety of the β3-adrenoreceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction. J Urol. 2013;190(4):1320–7.

    Article  CAS  PubMed  Google Scholar 

  8. Khullar V, Amarenco G, Angulo JC, et al. Efficacy and tolerability of mirabegron, a β3-adrenoreceptor agonist, in patients with overactive bladder: results from a randomised European–Australian phase 3 trial. Eur Urol. 2013;63(2):283–95.

    Article  CAS  PubMed  Google Scholar 

  9. Nitti V, Auerbach S, Martin N, et al. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol. 2013;189(4):1388–95.

    Article  CAS  PubMed  Google Scholar 

  10. Herschorn S, Barkin J, Castro-Diaz D, et al. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β3 adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology. 2013;82(2):313–20.

    Article  PubMed  Google Scholar 

  11. Chapple CR, Kaplan SA, Mitcheson D, et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β3-adrenoceptor agonist, in overactive bladder. Eur Urol. 2013;63(2):296–305.

    Article  CAS  PubMed  Google Scholar 

  12. Nitti VW, Khullar V, van Kerrebroeck P, et al. Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies. Int J Clin Pract. 2013;67(7):619–32.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. Nitti V, Herschorn S, Khullar V, et al. Efficacy of the selective β3-adrenoceptor agonist, mirabegron, in patients with overactive bladder (OAB) who discontinued prior antimuscarinic therapy due to insufficient effect: pooled analysis of three randomised phase III studies [abstract no. 351]. In: 37th Annual Meeting of the International Urogynecological Association, 2012.

  14. Chapple C, Nitti VW, Khullar V, et al. Onset of action of the β3-adrenoreceptor agonist, mirabegron, in phase II and III clinical trials in patients with overactive bladder. World J Urol. 2014;32(6):1565–72.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  15. Chapple C, Khullar V, Nitti VW, et al. Efficacy of the β3-adrenoreceptor agonist mirabegron for the treatment of overactive bladder by severity of incontinence at baseline: a post hoc analysis of pooled data from three randomised phase 3 trials. Eur Urol. 2015;67(1):11–4.

    Article  CAS  PubMed  Google Scholar 

  16. Yamaguchi O, Marui E, Kakizaki H, et al. Phase III, randomised, double-blind, placebo-controlled study of the β3-adrenoreceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder. BJU Int. 2014;113(6):951–60.

    Article  CAS  PubMed  Google Scholar 

  17. Kuo H-C, Lee K-S, Na Y, et al. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β3-adrenoreceptor agonist, in patients with overactive bladder in Asia. Neurourol Urodyn. 2014. doi:10.1002/nau.22645.

  18. Wagg A, Cardozo L, Nitti VW, et al. The efficacy and tolerability of the β3-adrenoreceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients. Age Ageing. 2014;43(5):666–75.

    Article  PubMed  Google Scholar 

  19. Nitti V, Chapple CR, Walters C, et al. Safety and tolerability of the β3-adrenoreceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12-week randomised phase III trials and of a 1-year randomised phase III trial. Int J Clin Pract. 2014;68(8):972–85.

    Article  CAS  PubMed  Google Scholar 

  20. Aballéa S, Maman K, Thokagevistk K, et al. Cost effectiveness of mirabegron compared with tolterodine extended release for the treatment of adults with overactive bladder in the United Kingdom. Clin Drug Investig. 2015;35(2):83–93.

    Article  PubMed Central  PubMed  Google Scholar 

  21. Sanford M. Mirabegron: a review of its use in patients with overactive bladder syndrome. Drugs. 2013;73(11):1213–25.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The manuscript was reviewed by: F. Araujo, Faculty of Experimental Sciences, Pablo de Olavide University, Seville, Spain; S. Saluja, Saran Ashram Hospital, Dayalbagh, Agra, India.

Disclosure

This article was updated from Drugs 2013;73(11):1213–25 [21] by salaried employees of Adis/Springer, and was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from comments received were made by the authors on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, North Shore, 0754, Auckland, New Zealand

    Mark Sanford & Katherine A. Lyseng-Williamson

Authors
  1. Mark Sanford
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Katherine A. Lyseng-Williamson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mark Sanford.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sanford, M., Lyseng-Williamson, K.A. Mirabegron: a guide to its use in overactive bladder syndrome in the EU. Drugs Ther Perspect 31, 107–111 (2015). https://doi.org/10.1007/s40267-015-0197-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-015-0197-x

Keywords

Search

Navigation